Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 4/20 | 0.45 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.42 |
| ▸ | AXL | P30530 | 12/20 | 0.42 |
| ▸ | MET | P08581 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16863203 | 0.86 | AXL (0.47) | HSPB1S1PR4AXLMETALDH1A1 | |
| SCHEMBL16863293 | 0.86 | HSPB1 (0.45) | HSPB1S1PR4AXLMETALDH1A1 | |
| SCHEMBL16863428 | 0.86 | AXL (0.57) | HSPB1AXLMET | |
| SCHEMBL16863301 | 0.84 | AXL (0.48) | HSPB1S1PR4AXLMETALDH1A1 | |
| SCHEMBL16863393 | 0.82 | AXL (0.50) | HSPB1AXLMETALDH1A1MAPT | |
| SCHEMBL16863289 | 0.82 | AXL (0.50) | HSPB1AXLMETALDH1A1MAPT | |
| SCHEMBL16863372 | 0.82 | AXL (0.52) | AXLMETALDH1A1MAPTMAPK1 | |
| SCHEMBL16863264 | 0.82 | AXL (0.58) | HSPB1AXLMET | |
| SCHEMBL16863397 | 0.82 | AXL (0.51) | HSPB1AXLMETMAPT | |
| SCHEMBL16863409 | 0.81 | AXL (0.65) | AXLMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148447-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES AND METHODS OF THEIR USE | IGNYTA, INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-9914731-B2 | Pyrazolo[1,5-a]pyridine derivatives and methods of their use | IGNYTA, INC. (US) | 2018-03-13 | — | — | US | disclosed |
| US-20160318929-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES AND METHODS OF THEIR USE | CEPHALON, INC. | 2016-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148447-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES AND METHODS OF THEIR USE | AXL, FLT3, ERBB2 | HSPB1 2376/4885S1PR4 1535/4885AXL 1/4885 |
| US-20160318929-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES AND METHODS OF THEIR USE | AXL, FLT3, ERBB2 | HSPB1 2376/4885S1PR4 1535/4885AXL 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.